Please assess the completion status of the following clinical trial:

Trial Title: A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women and men aged 18-70~* DSM-IV diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder by diagnostic interview and chart review~* Smoke at least 10 cigarettes per day~* Clinically stable, on a stable dose of antipsychotic (schizophrenia) or mood stabilizer (bipolar) medication for at least 1 month~* No current active suicidal ideation~* Expired air carbon monoxide (CO) concentration \>9 ppm~* Willing to take study medications and set a quit date within 2-3 weeks of beginning treatment and be willing to participate in the relapse prevention and follow-up portions of the study~* Women of childbearing potential must have a negative urine pregnancy test at baseline and agree to use an approved form of contraception during the study.~Exclusion Criteria:~* DSM-IV diagnosis of dementia, neurodegenerative disease, or other organic mental disorder~* Substance use disorder other than nicotine or caffeine in the last 6 months~* Major depressive disorder within the last 6 months~* Serious unstable medical illness including, cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or hematological disease such that hospitalization for treatment of that illness is likely within the next 2 months~* Life-threatening arrhythmia or cerebro-vascular event within 6 months, cardiovascular event within 2 months or uncontrolled hypertension~* History of multiple head injuries with neurological sequelae, a single severe head injury with lasting neurological sequelae, or current CNS tumor~* Liver function tests elevated over twice normal~* Renal insufficiency with estimated creatinine clearance \<40 ml/min~* Plan to continue use of tobacco products othe than cigarettes (e.g., cigar, pipe)~* Use of an investigational medication or device in the past 30 days~* Current suicidal or homicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Randomized Phase: Varenicline (Type: ACTIVE_COMPARATOR): Varenicline is a partial agonist at alpha4beta2 nicotinic acetylcholine receptors (nAChRs) and a full agonist at alpha 7 nAChRs that has been shown to be effective for smoking cessation compared with placebo and bupropion, with effects on abstinence rates for up to one year. Varenicline has demonstrated safety when dosed at 1 mg twice per day for up to one year. Because varenicline, at a dose of 1 mg twice per day, may be a more effective treatment for sustained abstinence than bupropion, it was chosen as the medication intervention for this study.
- Randomized Phase: Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).